Be A Freedom Fighter · Bill Library
HR 10787 — Access to Medical Supplies Act
Freedom score: -2 (scale −10 to +10)
- Individual rights: 0
- Property rights: 0
- Economic freedom: -1
- Privacy & due process: 0
- Government power: -1
Sponsor: Rep. Murphy, Gregory F. [R-NC-3] · Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (2026-10-09)
Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index
Findings — 7 highlighted provisions
Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.
- Sec. 1 — Short title See in text ↓
- Sec. 2 · Government Power — Social Security Act §1847(a)(2)(A): Excludes urological and ostomy supplies from the Medicare competitive acquisition program only for supplies furnished Jan. 1, 2028–Dec. 31, 2032. This temporarily shelters a product category from competitive procurement rather than eliminating the entire competitive-bidding system See in text ↓
- Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands See in text ↓
- Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation See in text ↓
- Sec. 4, new §1847(h)(1)–(3) · Government Power — Requires a demonstration starting no later than three years after enactment, in no more than three states for twelve months, evaluating supply access and patient outcomes. Requires pre-project survey, early re-survey and panel consultation when patients cannot obtain prior products See in text ↓
- Sec. 5, new §1847(i)(1) · Government Power — Restricts contracted suppliers from influencing patients to switch the physician/patient-selected brand, expressly including persuasion, advice and unsolicited information about other brands. That is a regulation of supplier communications and marketing See in text ↓
- Sec. 5, new §1847(i)(2) · Government Power — Requires a beneficiary-access process for the same or clinically comparable product; if not available through a contract supplier, the individual may obtain supplies from a different or noncontract supplier. This expands a beneficiary's options while narrowing covered suppliers' freedom to market alternative brands See in text ↓
Full text (introduced version)
18 of 18 text blocks highlighted. Source: GovInfo, fetched cached.
SECTION 1. SHORT TITLE.
Sec. 1 — Short title
SEC. 2. EXCLUDING UROLOGICAL AND OSTOMY SUPPLIES FROM COMPETITIVE ACQUISITION PROGRAMS UNDER THE MEDICARE PROGRAM FOR 5 YEARS.
Sec. 2 · Government Power — Social Security Act §1847(a)(2)(A): Excludes urological and ostomy supplies from the Medicare competitive acquisition program only for supplies furnished Jan. 1, 2028–Dec. 31, 2032. This temporarily shelters a product category from competitive procurement rather than eliminating the entire competitive-bidding system
SEC. 3. REQUIRING THE ESTABLISHMENT OF TECHNICAL EXPERT PANEL TO ANALYZE THE IMPACT OF INCLUDING UROLOGICAL AND OSTOMY SUPPLIES IN COMPETITIVE ACQUISITION PROGRAMS UNDER THE MEDICARE PROGRAM AND RECOMMEND CHANGES.
Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands
Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation
Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands
Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation
Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands
Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation
Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands
Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation
Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands
Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation
Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands
Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation
Sec. 3, new §1847(g)(1)–(3) · Government Power — Requires a technical expert panel within 90 days of enactment, with at least 15 patient, clinical, supplier and industry stakeholders; recommendations within one year of creation and periodically afterward concerning inclusion of these supplies and access to medically appropriate brands
Sec. 3, new §1847(g)(4)–(5) · Government Power — Requires the Secretary to implement competitive acquisition consistent with expert recommendations and publish panel minutes and documentation. Exact future conditions are contingent on the panel's recommendations and agency implementation
SEC. 4. ESTABLISHMENT OF DEMONSTRATION PROJECT TO ASSESS INCLUSION OF UROLOGICAL AND OSTOMY SUPPLIES IN THE COMPETITIVE ACQUISITION PROGRAM.
Sec. 4, new §1847(h)(1)–(3) · Government Power — Requires a demonstration starting no later than three years after enactment, in no more than three states for twelve months, evaluating supply access and patient outcomes. Requires pre-project survey, early re-survey and panel consultation when patients cannot obtain prior products
Sec. 4, new §1847(h)(1)–(3) · Government Power — Requires a demonstration starting no later than three years after enactment, in no more than three states for twelve months, evaluating supply access and patient outcomes. Requires pre-project survey, early re-survey and panel consultation when patients cannot obtain prior products
Sec. 4, new §1847(h)(1)–(3) · Government Power — Requires a demonstration starting no later than three years after enactment, in no more than three states for twelve months, evaluating supply access and patient outcomes. Requires pre-project survey, early re-survey and panel consultation when patients cannot obtain prior products
Sec. 4, new §1847(h)(1)–(3) · Government Power — Requires a demonstration starting no later than three years after enactment, in no more than three states for twelve months, evaluating supply access and patient outcomes. Requires pre-project survey, early re-survey and panel consultation when patients cannot obtain prior products
Sec. 4, new §1847(h)(1)–(3) · Government Power — Requires a demonstration starting no later than three years after enactment, in no more than three states for twelve months, evaluating supply access and patient outcomes. Requires pre-project survey, early re-survey and panel consultation when patients cannot obtain prior products
SEC. 5. PROHIBITION ON INFLUENCING AND INCENTIVIZING AND RIGHT TO PURCHASE THE SAME OR CLINICALLY COMPARABLE UROLOGICAL AND OSTOMY SUPPLIES.
Sec. 5, new §1847(i)(1) · Government Power — Restricts contracted suppliers from influencing patients to switch the physician/patient-selected brand, expressly including persuasion, advice and unsolicited information about other brands. That is a regulation of supplier communications and marketing
Sec. 5, new §1847(i)(2) · Government Power — Requires a beneficiary-access process for the same or clinically comparable product; if not available through a contract supplier, the individual may obtain supplies from a different or noncontract supplier. This expands a beneficiary's options while narrowing covered suppliers' freedom to market alternative brands
Sec. 5, new §1847(i)(1) · Government Power — Restricts contracted suppliers from influencing patients to switch the physician/patient-selected brand, expressly including persuasion, advice and unsolicited information about other brands. That is a regulation of supplier communications and marketing
Sec. 5, new §1847(i)(2) · Government Power — Requires a beneficiary-access process for the same or clinically comparable product; if not available through a contract supplier, the individual may obtain supplies from a different or noncontract supplier. This expands a beneficiary's options while narrowing covered suppliers' freedom to market alternative brands
Sec. 5, new §1847(i)(1) · Government Power — Restricts contracted suppliers from influencing patients to switch the physician/patient-selected brand, expressly including persuasion, advice and unsolicited information about other brands. That is a regulation of supplier communications and marketing
Sec. 5, new §1847(i)(2) · Government Power — Requires a beneficiary-access process for the same or clinically comparable product; if not available through a contract supplier, the individual may obtain supplies from a different or noncontract supplier. This expands a beneficiary's options while narrowing covered suppliers' freedom to market alternative brands
Sec. 5, new §1847(i)(1) · Government Power — Restricts contracted suppliers from influencing patients to switch the physician/patient-selected brand, expressly including persuasion, advice and unsolicited information about other brands. That is a regulation of supplier communications and marketing
Sec. 5, new §1847(i)(2) · Government Power — Requires a beneficiary-access process for the same or clinically comparable product; if not available through a contract supplier, the individual may obtain supplies from a different or noncontract supplier. This expands a beneficiary's options while narrowing covered suppliers' freedom to market alternative brands
Findings source: bill-scores-v2-batch43-findings-2026-11-15.md. Highlights come only from that file; no finding, score, or provision was invented for this page.
What you can do
Contact your U.S. Representative and Senators about this bill.
Find your Representative Contact your Senators
Spot an error on this page? Report it.